Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2a Study of an Immunotherapeutic Vaccine, DPX-Survivac, Alone or with Low dose Cyclophosphamide in Primary Glioblastoma Patients Receiving Standard of Care Therapy

Next Previous
Trial Profile

Phase 2a Study of an Immunotherapeutic Vaccine, DPX-Survivac, Alone or with Low dose Cyclophosphamide in Primary Glioblastoma Patients Receiving Standard of Care Therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs EMD 640744 (Primary) ; Cyclophosphamides
  • Indications Glioblastoma
  • Focus Biomarker; Pharmacodynamics

    • Most Recent Events

    • 26 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top